ACM
SPRY icon

Aquatic Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Aquatic Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,855
Closed -$111K – 1704
2026
Q1 		$111K Sell
13,855
-22,182
-62% -$213K ﹤0.01% 1085
2025
Q4 		$420K Sell
36,037
-69,714
-66% -$678K 0.01% 789
2025
Q3 		$1.06M Buy
105,751
+57,063
+117% +$819K 0.02% 656
2025
Q2 		$850K Buy
+48,688
New +$703K 0.02% 695
2024
Q2 		– Sell
-1,100
Closed -$11.2K – 1573
2024
Q1 		$11.2K Buy
+1,100
New +$8.2K ﹤0.01% 1136
2023
Q3 		– Sell
-6,900
Closed -$46K – 1620
2023
Q2 		$46K Buy
+6,900
New +$46.1K ﹤0.01% 1005

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Aquatic Capital Management's SPRY Position: Q2 2026 in Review

Aquatic Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 13,855 shares — an estimated $111K sold.

Aquatic Capital Management first reported a position in SPRY in Q2 2023 and held it in 6 quarters. The position peaked at $1.06M in Q3 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Aquatic Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 13,855 ARS Pharmaceuticals shares in Q2 2026, an estimated $111K.
  • Aquatic Capital Management first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Aquatic Capital Management's ARS Pharmaceuticals position peaked at $1.06M in Q3 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.